RE:RE:RE:RE:RE:Honestly Bull. We all knew the max data was 6 patients w 2nd treatment and that would replicate phase 1 safety signals to be cute u could hide there behind clinical relevancy for efficacy claims until 360 day. But we all know.
vestor111 wrote:
The patents alone are worth far more than the cap value of the company.
The discovery that Ruthenium engineered compounds can ride for free on Transferrin is no small discovery. And then to be taken straight into cancer cells and thru all the various blodd barriers.
Think about zinc...an essential metal but it needs an ionophore to penetrate the cell wall. TLD-1433 us welcomed in like food.
Cancer thinks Rutherrin is iron... it uses the same "lock and key" mechanism of the outer valance shell look-alike that gets Transferrin bounds to ...It is the same outer valance lock and key mechanism.
1433 fools Transferrin the same way it fool's the Transferrin receptors on the cancer cells outer walls. FOOD!!! Deadly FOOD! Just wait and turn on the lights.
Automatic. Built-in. Elegant. (And the bonus...it explodes cancer cells in a manner that alerts the immune system.)
Come up with a better story to getting rid of cancer other than prevention.
Dr Mandel wrote the Rutherrin patent to cover a wide waterfront of compounds that is now under research around the world. That makes TLT very valuable. The world will find out.
But it takes time...longer than most would have believed.
With a 3 to 6 month Corona break along the way - which doesn't help. And that doesn't change the science...just prolongs what we have been waiting for. (Painfully.)